TrialInternational journal of chronic obstructive pulmonary disease2019

Imidafenacin, An Orally Active Muscarinic Receptor Antagonist, Improves Pulmonary Function In Patients With Chronic Obstructive Pulmonary Disease: A Multicenter, Randomized, Double-Blind, Placebo-Controlled 3×3 Crossover Phase II Trial.

Kentaro Machida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.